NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals announced that its board has approved a share repurchase program on Wednesday, March 28th 2018, which authorizes the company to buyback $7,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 2.7% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its earnings results on Tuesday, November, 12th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. The firm earned $14.23 million during the quarter. Avadel Pharmaceuticals had a negative net margin of 136.46% and a negative return on equity of 608.01%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Avadel Pharmaceuticals.

Avadel Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$55 million, compared to the consensus revenue estimate of $$50.99 million.

3 equities research analysts have issued 12-month price targets for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

News headlines about AVDL stock have been trending neutral this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include I-Mab (ARQT), Achillion Pharmaceuticals (ACHN), Amphastar Pharmaceuticals (AMPH), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), CannTrust (CNTTF), Aprea Therapeutics (APRE), DiaMedica Therapeutics (DMCAF), Assembly Biosciences (ASMB), Axovant Sciences (AXON), Ardelyx (ARDX), Aptorum Group (APM), AnaptysBio (ANAB), Avedro (AVDR) and Gemphire Therapeutics (GEMP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Brandes Investment Partners LP (9.75%), Broadfin Capital LLC (2.75%), Renaissance Technologies LLC (2.28%), Iridian Asset Management LLC CT (0.83%), Keel Point LLC (0.11%) and Perceptive Advisors LLC (0.02%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP and Broadfin Capital LLC. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was bought by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Keel Point LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Carmichael Hill & Associates Inc., Steward Partners Investment Advisory LLC and UBS Group AG. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis and Michael S Anderson. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $7.14.

Avadel Pharmaceuticals has a market capitalization of $267.39 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.